Press releases

Stayble Therapeutics AB ("Stayble" or "the Company") announced today that the South African patent office, as the first country, has approved the Company's patent for...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2024. The report is available as an attached document and on the...

Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's phase Ib study has reached the follow-up goal of at least 18 patients...

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,...

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 2024. The report is available as an attached...

Stayble Therapeutics AB, org.nr 559024-8372 ("Bolaget"), har hållit årsstämma den 15 maj 2024 kl. 13.00 på Bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Vid...

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2023. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 15 maj 2024 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg....

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's scientific abstract regarding the treatment concept for herniated discs has been accepted for a...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been included in the ongoing phase Ib clinical study with STA363...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...

Stayble Therapeutics AB ("Stayble" or the "Company") today presents the final data analysis of the Company's phase IIb study with STA363 against chronic disc-related back...

Stayble Therapeutics AB ("Stayble" or the "Company") today presents further analyses from the Phase IIb study on degenerative disc disease (DDD) and its impact on...

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...

Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc...

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that it has entered into an agreement with the transaction advisor Ferghana Partners (“Ferghana”) ahead of...

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company will participate in the investor meeting "Investera som proffsen," organized by Financial Stockholm...

Stayble Therapeutics AB ("Stayble" or the "Company") today announces that the Last Patient Last Visit (LPLV) in the Phase 2b clinical study in degenerative disc...

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the first patient has been enrolled in the Company's Phase 1b clinical study with STA363...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...

Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease...

Stayble Therapeutics AB ("Stayble" or the "Company") announces that approximately 90% of all patients in the Company's ongoing Phase IIb study in degenerative disc disease...

As part of Stayble Therapeutics’ (“Stayble”) strategy to find a development partner, the company participated in the international Bio International Convention in Boston last week....

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 1 juni 2023 kl. 14.00 på bolagets kontor på Arvid Hedvalls Backe 4 i...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company has strengthened its scientific advisory board with Professor Daisuke Sakai, MD, PhD, as new...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Stayble Therapeutics AB (”Stayble” or ”the Company”) today announces that Jarkko Kalliomäki will assume the role of Chief Medical Officer (CMO) in the Company. Jarkko...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Stayble Therapeutics AB (”Stayble” or the ”Company”) is currently conducting a phase 2b study with the drug candidate STA363. The Company now presents positive interim...

In connection with the ongoing rights issue, Stayble Therapeutics CEO Andreas Gerward makes a number of presentations and interviews. More information about the rights issue,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...

Stayble Therapeutics AB ("Stayble" or "the Company") announces that the Company will participate in the annual Life-Science Day in Gothenburg, Sweden, which takes place on...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...

Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company's Phase IIb study has reached the follow-up goal of 100 patients completing their...

Stayble Therapeutics AB ("Stayble" or the "Company") announces that the Company's ongoing Phase 2b study has been accepted for poster presentation at the 4th European...

On Thursday, December 1, Stayble Therapeutics AB ("Stayble" or the "Company") will participate in ProHearing's investor event. The Company's CEO, Andreas Gerward, will give an...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the third quarter of 2022. The report is available as an attached...

Andreas Gerward, CEO of Stayble Therapeutics AB, will attend Stora Aktiedagen in Gothenburg on 8 November 2022. Topics to be discussed include Stayble's market potential,...

Stayble Therapeutics AB ("Stayble" or the "Company") provides an update on the ongoing Phase IIb study. The company sees continued good compliance and approx. 70%...

Stayble Therapeutics AB ("Stayble" or the "Company") has recently entered into an agreement with the analysis company Kalqyl AB ("Kalqyl") which has now published the...

Stayble Therapeutics AB (”Stayble” or the ”Company”) announces today that the Company’s CEO Andreas Gerward has purchased 15,000 shares in the Company for a total...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the...

Idag, den 1 juni 2022, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the first quarter of 2022. The interim report is available as an...

Stayble Therapeutics AB (“Stayble” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. Stayble has terminated its existing liquidity providing...

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby publishes the Annual Report (in Swedish) for the financial year of 2021.

Stayble Therapeutics AB (“Stayble” or “the Company”) announces today that the Company has recruited 75% of all patients with chronic disc-related back pain to the...

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 14 March 2022 at Aktiedagen Stockholm 2022, an event arranged by Swedish Shareholders´ Association´s.

Stayble Therapeutics AB comments on the Company's ongoing clinical phase IIb study, which is ongoing in Russia, among other places. The company follows the development...

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is...

Analysguiden has completed an analysis of Stayble Therapeutics. The analysis is available at the following link: https://www.aktiespararna.se/analysguiden/nyheter/initieringsanalys-stayble-therapeutics-unik-behandling-diskrelaterad-ryggsmarta

Stayble Therapeutics' CEO Andreas Gerward gave a presentation on 30 November 2021 at Stora Aktiedagen Stockholm 2021, an event arranged by Swedish Shareholders´ Association´s. The...

Göteborg, 18 november 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för tredje kvartalet (juli-september) 2021

Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data...

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning...

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*.

Stayble Therapeutics announced today that the company is strengthening its team by recruiting Dr. Sara Richardson in the newly created role VP CMC and Regulatory...

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to...

Stayble Therapeutics today announced that the company’s scientific advisory board gains new expertise through the appointment of Professor Hans Jörg Meisel, Berlin, Germany. Prof. Meisel...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8...

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection...

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

Stayble Therapeutics today announced that the company’s continue to strengthen its scientific advisory board with two new members – Dr. Aaron Calodney and Dr. Douglas...

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019,...

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price...

Today is the first day of exercise TO1 for subsription to company shares that extend to December 1, 2020. Every one warrent gives the right...

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of...

Stayble Therapeutics today announced that Professor Anders Lehmann, VP Development, will give a talk entitled ”Sclerosation of the intervertebral disc using lactic acid in patients...

Stayble Therapeutics today announced that the Company has initiated the first clinic in Spain for its clinical phase 2b study with the drug candidate STA363....

A scientific article based on pre-clinical studies and the clinical phase 1b study with STA363 has been published in the highly prestigious scientific journal Spine.

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering...

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously...

Stayble announces today, July 2, 2020, that the Company has initiated the first clinic in the Netherlands and now recruiting patients. The company has previously...

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated...

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were...

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

The Company announces that the investigational drug (two doses of STA363 and placebo) now is manufactured and quality assured by our partner APL.

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study...

The company can announce that an additional important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted...

The company can announce that an important step for starting the phase 2b clinical trial during Q2 has been completed. The company has submitted applications...

Today, March 9 2020, marks the first day of trading in Stayble Therapeutics AB’s (“Stayble” or “the Company”) shares and warrants on Nasdaq First North...

Stayble Therapeutics AB (”Stayble” or the “Company”) has appointed Mangold Fondkommission as liquidity provider for the Company's share on Nasdaq First North Growth Market with...

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES (INCLUDING ITS TERRITORIES AND PROVINCES, EVERY STATE OF THE UNITED...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its half-year report for 2024. The report is available as an attached document and on the...

Stayble Therapeutics AB announces that Erik Kullgren has been appointed as the new CFO, effective August 1, 2024.

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,...

EJ FÖR PUBLICERING, DISTRIBUTION ELLER OFFENTLIGGÖRANDE, DIREKT ELLER INDIREKT, HELT ELLER DELVIS, INOM ELLER TILL USA, AUSTRALIEN, HONGKONG, JAPAN, KANADA, NYA ZEELAND, SCHWEIZ, SINGAPORE, SYDAFRIKA,...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its interim report for the first quarter of 2024. The report is available as an attached...

Stayble Therapeutics AB, org.nr 559024-8372 ("Bolaget"), har hållit årsstämma den 15 maj 2024 kl. 13.00 på Bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg. Vid...

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2023. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 15 maj 2024 kl. 13.00 på bolagets kontor på Lennart Torstenssonsgatan 8 i Göteborg....

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby publishes its year-end report for 2023. The report is available as an attached document and on the...

Republishes with MAR text in the press release. No changes have been made to the press release or the attached report. Stayble Therapeutics AB ("Stayble"...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the third quarter of 2023. The report is available as an attached...

Stayble Therapeutics AB ("Stayble" or the "Company") today presents top-line data from the Company's phase IIb study with STA363 for the treatment of degenerative disc...

Stayble Therapeutics AB ("Stayble" or "the Company") announces today that the Company has terminated the agreement regarding the liquidity provider with Lago Kapital AB ("Lago")....

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its half-year report for 2023. The report is available as an attached document and on the...

Stayble Therapeutics AB, org.nr 559024-8372 (”Bolaget”), har hållit årsstämma den 1 juni 2023 kl. 14.00 på Bolagets kontor på Arvid Hedvalls Backe 4 i Göteborg....

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its quarterly report for the first quarter of 2023. The report is available as an attached...

Stayble Therapeutics AB (”Stayble” eller ”Bolaget”) publicerar idag årsredovisningen för 2022. Årsredovisningen finns tillgänglig på bolagets hemsida (https://staybletherapeutics.com/sv/investerare/finansiella-rapporter/) och bifogad i detta utskick.

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 1 juni 2023 kl. 14.00 på bolagets kontor på Arvid Hedvalls Backe 4 i...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Idag den 16 mars 2023 hölls extra bolagsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the Company has received approval to initiate the first clinical trial of its disc herniation...

Aktieägarna i Stayble Therapeutics AB, org.nr: 559024–8372, kallas härmed till extra bolagsstämma torsdagen den 16 mars 2023 kl. 14.00 i på bolagets kontor, Arvid Hedvalls...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, JAPAN, CANADA, NEW ZEELAND, SOUTH AFRICA, HONG KONG, SWITZERLAND,...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes its year-end report for 2022. The report is available as an attached document and on the...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the third quarter of 2022. The report is available as an attached...

Stayble Therapeutics AB ("Stayble" or the "Company") announces today that the last patient has been recruited in the ongoing phase IIb clinical trial of STA363...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the half-year report for 2022. The report is available as an attached document and on the...

Idag, den 1 juni 2022, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

Stayble Therapeutics AB ("Stayble" or the "Company") hereby publishes the interim report for the first quarter of 2022. The interim report is available as an...

Stayble Therapeutics AB (“Stayble” or “the Company”) has entered into a liquidity providing agreement with Lago Kapital AB. Stayble has terminated its existing liquidity providing...

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby publishes the Annual Report (in Swedish) for the financial year of 2021.

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

Stayble Therapeutics AB (”Stayble” or ”the Company”) hereby announces that the Company has entered into an agreement with Svensk Kapitalmarknadsgranskning AB (”SKMG”) regarding the service...

Stayble Therapeutics AB (”Stayble” or the ”Company”) published its year-end report for the period January 2021 – December 2021 today. The report (in Swedish) is...

Göteborg, 18 november 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för tredje kvartalet (juli-september) 2021

Stayble Therapeutics AB (“Stayble” or “the Company”) is currently conducting a phase 2b study with the drug candidate STA363. The company has analyzed blinded data...

Göteborg, 16 augusti 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för andra kvartalet (april– juni) 2021

Idag, den 2 juni 2021, hölls årsstämma i Stayble Therapeutics AB. Nedan följer en sammanfattning av de beslut som fattades. Samtliga beslut fattades med erforderlig...

Göteborg, 17 maj 2021 – Stayble Therapeutics AB publicerar kvartalsrapport för första kvartalet (januari – mars) 2021

Aktieägarna i Stayble Therapeutics AB, org.nr 559024-8372, kallas till årsstämma den 2 juni 2021 kl. 12.00 på bolagets kontor på Arvid Hedvalls Backe 4, våning...

Gothenburg, May 21, 2021 – Stayble Therapeutics, today announced the publication of the Annual Report 2020*.

Stayble Therapeutics announced today that recruiting patients for the company's ongoing Phase 2b study with the drug candidate STA363 is slower than expected due to...

Stayble Therapeutics AB (“Stayble” or the “Company”) hereby announces that the last day of trading in Paid Subscription Shares (Sw. BTA) will be on 8...

The subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) rights issue ended on 17 February 2021. The rights issue was subscribed to a...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby informs that the first day of trading in subscription rights and paid subscribed share ("BTA"), in connection...

Today is the first day of the subscription period in Stayble Therapeutics AB’s (“Stayble” or the “Company”) new issue of shares with preferential rights for...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

Stayble Therapeutics AB (”Stayble” or the ”Company”) hereby publishes prospectus in connection with the Company’s forthcoming rights issue, with a subscription period that begins Wednesday,...

Stayble Therapeutics AB (“Stayble” or “the Company”) announces that the Board of Directors, with support of the authorization from the Annual General Meeting in 2019,...

In total, 7,122 warrants were exercised, corresponding to approximately 0.3 percent of the outstanding warrants, for subscription of 7 122 shares at a subscription price...

Stayble Theraputics AB carried out during the first quarter of 2020 in conection with the listing on Nasdaq First North Growt Market, an issue of...

Stayble Therapeutics announces today, July 31, 2020, that the first patient has been treated in Stayble’s clinical phase 2b study. STA363 is targeting patients suffering...

Stayble announces today, June 16, 2020, that the Company´s clinical phase 2b study with STA363 has started with the first clinic in Russia being initiated...

Today, June 8, 2020, the annual general meeting of Stayble Therapeutics AB was held. Below is a summary of the resolutions made. All resolutions were...

Stayble announces today, May 20, 2020, that the Russian regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

Stayble announces today, May 1, 2020, that the Spanish regulatory authorities have approved the Company´s clinical trial application on the clinical phase 2b study with...

Gothenburg, April 21, 2020 – Stayble Therapeutics, today announced the publication of the Annual Report 2019.

Stayble announces today, March 17 2020, that the Dutch regulatory authorities (RA) have approved the Company´s clinical trial application on the clinical phase 2b study...

Nasdaq Stockholm AB has approved Stayble Therapeutics AB’s (”Stayble” or ”the Company”) application for listing of the Company’s shares and warrants of series TO1 on...